2026年1月26日，信邦制药（002390.SZ）方面披露，公司及下属子公司需补缴税款及滞纳金5078.69万 元，其中，公司的金额为269.57万元，下属子公司的金额为4809.12万元。本次补缴不涉及行政处罚。 上述补缴税款及滞纳金将计入信邦制药2025年当期损益。 2025年前三季度，信邦制药营业收入为42.66亿元，同比减少6.55%；归属于上市公司股东的净利润为 1.52亿元，同比减少13.74%。此次补缴税款及滞纳金预计将对信邦制药2025年全年业绩造成较大不利影 响。 信邦制药主营业务包括医疗服务、医药流通、医药制造。信邦制药旗下医疗机构主要有贵州医科大学附 属肿瘤医院、贵州医科大学附属白云医院、贵州医科大学附属乌当医院等。在医药流通方面，信邦制药 为贵州省医药流通龙头企业。 不久前，贵州省开阳县人民检察院对信邦制药涉嫌单位行贿案已向法院提起公诉。 （文章来源：中国经营报） ...

Core Viewpoint - The company is focused on the ecological layout in the pharmaceutical and health industry, with its main business covering pharmaceutical distribution, digital empowerment, and health services [1] Summary by Categories Business Focus - The company will concentrate on its core strategy and continue to deepen its layout across the entire pharmaceutical health industry chain [1] Current Collaborations - As of now, the company has no business cooperation arrangements with military enterprises [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所发布的上市公司分行业信息披露指引及《关于做好主板 上市公司 2025 年第三季度报告披露工作的重要提醒》相关要求，现将公司 2025 年前三季度主要经营数据披露如下： 一、报告期内，公司主营业务收入按分行业经营情况如下： 注：此表中收入类别的"其他"主要系全资子公司北京康惠智创科技有限公司的相关数 据，该子公司 2025 年 5 月设立，无上年数据。 二、报告期内，公司主营业务收入按产品用途经营情况如下： 证券代码：603139 证券简称：康惠股份 公告编号：2025-071 陕西康惠制药股份有限公司 关于2025年前三季度主要经营数据的公告 单位：万元 项 目 营业收入 营业成本 毛利率（%） 营业收入比上 年增减（%） 营业成本比上 年增减（%） 毛利率比上 年增减(%) 本公告之经营数据未经审计，提醒投资者审慎使用上述数据，注意投资风险。 陕西康惠制药股份有限公司董事会 2025 年 10 月 30 日 妇科类 2,494.58 1,165.74 53.2 ...

Group 1 - The core point of the article is that Kanghui Pharmaceutical announced significant shareholding and pledge details from a major shareholder, along with its revenue composition for the first half of 2025 [1] Group 2 - Kanghui Pharmaceutical's major shareholder, Shanghai Chuangxiangying Enterprise Management Partnership, holds approximately 5.99 million shares, accounting for 6% of the total share capital [1] - As of the announcement date, Chuangxiangying has pledged about 4 million shares, which is 66.67% of its holdings and 4% of the total share capital [1] - For the first half of 2025, Kanghui Pharmaceutical's revenue composition is as follows: 60.68% from pharmaceutical manufacturing, 36.79% from pharmaceutical distribution, and 2.53% from other businesses [1] - The current market capitalization of Kanghui Pharmaceutical is 2.4 billion yuan [1]

Group 1 - The company Guofa Co., Ltd. (SH 600538) announced the convening of its 11th Board of Directors' 17th meeting on July 31, 2025, to discuss the election of new committee members [2] - For the fiscal year 2024, the revenue composition of Guofa Co., Ltd. is as follows: pharmaceutical distribution accounts for 53.64%, judicial appraisal for 34.87%, pharmaceutical manufacturing for 10.41%, other businesses for 0.64%, and other categories for 0.44% [2]